Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1-Reference-Cited by-同舟云学术

Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

Published:2020-10-20 Issue:11 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Vaddady Pavan¹,Kandala Bhargava¹,Yee Ka Lai¹

Affiliation:

1. Merck & Co., Inc., Kenilworth, New Jersey, USA

Abstract

Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen (This study has been registered at ClinicalTrials.

Funder

Merck Sharp & Dohme Corp.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00590-20

Reference11 articles.

1. Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel

2. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs

3. Merck Sharp & Dohme Corp. 2019. PIFELTRO (doravirine) prescribing information. Merck & Co, Inc, Whitehouse Station, NJ. https://www.merck.com/product/usa/pi_circulars/p/pifeltro/pifeltro_pi.pdf. Accessed 16 March 2020.

4. Merck Sharp & Dohme Corp. 2019. DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate) prescribing information. Merck Sharp & Dohme Corp, Whitehouse Station, NJ. https://www.merck.com/product/usa/pi_circulars/d/delstrigo/delstrigo_pi.pdf. Accessed 16 March 2020.

5. Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population pharmacokinetic analysis of doravirine in real‐world people with HIV;British Journal of Clinical Pharmacology;2024-01-16

2. Successful treatment by doravirine with cobicistat-boosted darunavir for end-stage renal failure under chronic haemodialysis;Journal of Antimicrobial Chemotherapy;2021-01-25